Browse the corpus

Insulin lispro, an FDA-approved insulin analog, is an effective treatment for regulating hyperglycemia in type 1 and 2 diabetes. This medication extends its utility beyond its primary indication, finding application in off-label uses such as managing mild-to-moderate diabetic ketoacidosis, gestational diabetes, and mild-to-moderate hyperosmolar hyperglycemic state. The potency of insulin lispro stands at parity with human insulin, with each unit demonstrating equivalent efficacy in lowering glucose levels. This activity covers their mechanisms, adverse event profiles, eligible patient populations, drug interactions, and monitoring. The content underscores the significance of rapid-acting insulin, particularly insulin lispro, in optimizing patient outcomes within diabetes care. Objectives: Identify the appropriate indications for insulin lispro therapy based on patient characteristics and medical conditions. Screen patients for contraindications or potential risks associated with insulin lispro therapy, such as hypersensitivity reactions or specific medical conditions. Implement insulin lispro therapy according to established protocols and guidelines, including proper dosage calculations and administration techniques. Develop effective communication with patients about the proper use, self-administration techniques, and potential side effects of insulin lispro using the interprofessional healthcare team model. Access free multiple choice questions on this topic.

Intentional or accidental administration of excessive insulin lispro outside the body's needs will result in hypoglycemia. Signs and Symptoms of Overdose Mild to moderate hypoglycemia is evidenced by a blood glucose level less than 70 with or without the following symptoms: irritability, tachycardia, shakiness, lightheadedness or dizziness, anxiety or nervousness, double or blurred vision, mild confusion, sweating, and clamminess. Management of Overdose Mild-to-moderate hypoglycemia can be treated with an oral intake of 15 grams of carbohydrates, such as 4 ounces of fruit juice, 8 ounces of milk, or a piece of hard candy. Symptoms should improve within 15 minutes, but if they do not and blood glucose is still under 70, another 15 grams of carbohydrate should be taken. This cycle of eating 15 grams of carbohydrates, waiting 15 minutes, and then reassessing symptoms and blood glucose level can be repeated approximately 3 times before the patient should seek medical attention. Alpha-glucosidase inhibitors can delay the absorption of glucose administered as complex carbohydrates, and their use merits consideration during an emergency. Severe hypoglycemia is evidenced by more serious symptoms, including concentration problems, seizures, unconsciousness, and even death. Patients with severe hypoglycemia require the administration of glucagon, the principal rapid-acting counterregulatory hormone that raises the glucose concentration in the bloodstream. Patients on insulin should have a glucagon kit prescribed by their physician or advanced practice practitioner. The pediatric dosage is 0.02 to 0.03 mg/kg per dose for patients weighing less than 20 kilograms. The dose can be administered every 15 minutes as needed. For pediatric patients greater than 20 kilograms and adults, the dosage is 1 mg and can be administered every 15 minutes as needed. Patients requiring glucagon should be taken to a medical facility without delay. IV dextrose should be started immediately if they fail to respond to glucagon. Dasiglucagon is a glucagon analog approved by the FDA for managing severe hypoglycemia in 2021. This is a ready-to-use formulation, does not need reconstitution before injection, and can be used immediately in life-threatening hypoglycemia.[32]

Insulin lispro is frequently prescribed by physicians, advanced practice practitioners, internists, endocrinologists, and other healthcare workers to manage hyperglycemia. Clinicians who prescribe this insulin must understand that it can rapidly cause hypoglycemia. Thus, monitoring of blood glucose levels is critical. The most common adverse effect found in patients using insulin lispro is hypoglycemia. For this reason, close glucose monitoring is recommended for all patients with diabetes, and any changes made to the dosing should be done under medical supervision. Hypokalemia is another adverse effect to pay close attention to, especially with patients who are using potassium-lowering drugs or taking drugs sensitive to serum potassium levels. Nurses and pharmacists should educate patients regarding adverse effects, including injection site reactions and lipodystrophy at the injection site. Pharmacists should verify the product name and dose, perform medication reconciliation, and consult with the clinicians for errors or concerns. Endocrinologists should be consulted if there is a failure to achieve glycemic goals. Patients with hypoglycemia require prompt stabilization by emergency physicians.